The clinical significance of Rho in cancer is further implicated by a discovery that a RhoA GAP named Dlc-1 (deleted liver cancer 1) functions as a tumor suppressor in humans (47)

The clinical significance of Rho in cancer is further implicated by a discovery that a RhoA GAP named Dlc-1 (deleted liver cancer 1) functions as a tumor suppressor in humans (47). phosphorylation. mDia1-deficient cells show reduced transformationin vitroas examined by focus formation and colony Gefitinib (Iressa) formation in soft agar and exhibit suppressed tumorigenesis and invasion when implanted in nude micein vivo. Given overexpression of c-Src in various cancers, these findings suggest that Rho-mDia1 signaling facilitates malignant transformation and invasion by manipulating the actin cytoskeleton and targeting Src to the cell periphery. The small GTPase Rho functions as a molecular Gefitinib (Iressa) switch in cell morphogenesis through remodeling of the actin cytoskeleton (3,14). Rho cycles between the inactive GDP-bound form and the active GTP-bound form. This process is controlled by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs) specific to Rho; the former group catalyzes the exchange of GDP to GTP (50), and the latter accelerates the hydrolysis of bound GTP (24). When Rho is activated in fibroblasts, actin stress fibers are formed. Rho proteins are frequently overexpressed in human cancers, such as cancers of the colon and breast and lung and testicular germ cell tumors (34). A positive correlation between the expression level of RhoA and disease progression was also reported in breast cancer and testicular germ cell tumors. RhoC, on the other hand, has been repeatedly identified as a gene positively associated with metastasis (4,21,40). The clinical significance of Rho in cancer Gefitinib (Iressa) is further implicated by a discovery that a RhoA GAP named Dlc-1 (deleted liver cancer 1) functions as a tumor suppressor in humans (47). Thus, it was known for some time that heterozygous deletions on chromosome 8p22 are common in human tumors, such as cancers of the breast, prostate, lung (5,22), and especially liver (15). Recent studies have revealed a strong association of deletion of DLC-1 in this region with clinical cancers, and complementaryin vitroexperiments showed that DLC-1 functions as a potent tumor suppressor, depletion of which causes RhoA hyperactivation and results in tumorigenesis in harmony with other oncogenes, such as Myc and Ras (47). Importantly, heterozygous deletions in chromosome Gefitinib (Iressa) 8p22 are found to be nearly as common as that of TP53 in clinical cancers, indicating the significant importance of DLC-1 and Rho signaling in clinical tumors (18). Consistent with these findings, there are several reports on the requirement of Rho activity in cell transformationin vitro. For example, coexpression of Raf and dominant active RhoA facilitates focus formation, and expression of dominant-negative RhoA suppresses oncogenic Ras-induced focus formation in NIH 3T3 cells (30). In addition, active forms of Rho GEFs, such as Dbl and Ect2, have potent transforming activities in cultured cellsin vitro(31). Thus, there are amplein vitroand clinical data indicating the involvement of Rho signaling in oncogenesis. Cell transformation often leads to a change in cell morphology. This morphological change associates with a change in the organization of actin filaments. Nontransformed cells often have thick bundled actin fibers known as stress fibers. When transformed by some oncogenes, such as Ras and v-Src, the actin stress fibers disappear and the cells dramatically alter their shape to the round refractile cell body (49). Alternatively, actin dot structures called podosomes are often formed. This remodeling of the cytoskeleton is believed to contribute to several aspects of the transformed phenotype, including adhesion-independent cell Rabbit Polyclonal to PTGIS growth and increased migration abilities. Such actin remodeling associated with oncogenesis appears at odds with the requirement of Rho signaling in oncogenesis, because Rho activation leads to formation of actin fibers. Thus, there is a paradox of why transformed cells require Rho signaling yet show dissolution of actin cytoskeleton (27). Among many Rho effectors, two effector molecules, named mDia (44) and ROCK (11), have important roles in actin cytoskeleton remodeling (27). mDia produces straight actin filaments by catalyzing actin nucleation and polymerization, and ROCK activates myosin to cross-link actin filaments for induction of actomyosin bundles and contractility. Further, mDia is potentially linked to Rac activation and membrane ruffle formation through c-Src-induced phosphorylation of focal adhesion proteins, and ROCK antagonizes this mDia action (42). Thus, actin remodeling inside the cell can be determined primarily by the balance between mDia and ROCK activities. Of the two, the involvement of ROCK in tumors has been widely examined by the use of its small Gefitinib (Iressa) molecule inhibitors, such as Y-27632 (26,43), and the Rho-ROCK pathway has been strongly implicated in cancer migration and tumor metastasis and invasion. On the other hand, the role of ROCK in oncogenesis remains ambiguous. While its requirement in Ras-induced cell transformation was indicated by the use of Y-27632, examination.